SAN FRANCISCO, Mar 11: A single dose of an experimental Roche biotech drug that blocks inflammation reduced damage to the heart during artery clearing angioplasty procedures, according to data from a midstage trial presented on Sunday. The drug, inclacumab, was significantly better than a placebo in decreasing levels of molecular markers, or enzymes, that are used to diagnose heart attacks and heart damage in patients also taking standard drugs, such as cholesterol lowering statins, researchers said. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel